Gilead Sciences announced it will present new clinical data for two key drugs, Livdelzi and Hepcludex, at The Liver Meeting 2026. This includes late-breaking Phase 3 results for Livdelzi in primary biliary cholangitis, which could significantly impact its market potential and competitive landscape.
Gilead Sciences is set to present 21 abstracts at The Liver Meeting 2026, with a focus on late-breaking Phase 3 data for Livdelzi (seladelpar) in primary biliary cholangitis (PBC) and new long-term data for Hepcludex (bulevirtide-gmod) in chronic hepatitis delta virus. The Livdelzi data, particularly on alkaline phosphatase normalization, is crucial as it could solidify its position as a significant treatment option in the PBC market, directly competing with Intercept Pharmaceuticals' Ocaliva. Positive results could drive GILD's stock higher in the short to medium term, while potentially putting pressure on ICPT. The Hepcludex data will reinforce its long-term efficacy and safety profile, supporting its market adoption. This event represents a key opportunity for traders to assess the competitive landscape in liver diseases and the future revenue potential of Gilead's pipeline.